Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:48 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 4,127 matching trials from the local directory fallback.

Filters: Chicago, Illinois Clear all

Conditions: Bronchial Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor, Meningioma, Neuroendocrine Tumor Metastatic, Neuroendocrine Tumors Unresectable, Paraganglioma, Pheochromocytoma
Interventions: [203Pb]VMT-α-NET, [212Pb]VMT-α-NET; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Jacksonville, Florida • Miami, Florida • Orlando, Florida + 17 more

Conditions: Plasma Cell Myeloma Refractory
Interventions: Belantamab mafodotin, Belumosudil, Dexamethasone, Evorpacept, Isatuximab, Pegenzileukin, Pomalidomide, SAR439459; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Ann Arbor, Michigan + 2 more

Conditions: Acute Myocardial Infarction, Arterial Embolism, Coronary Artery Lesions, Restenoses, Coronary, Venous Embolism
Interventions: Coronary and peripheral guidewires, Coronary and peripheral stents, Coronary dilatation catheters, Measurement and imaging (FFR and OCT), Pacing catheters, Peripheral dilatation catheters, Vascular access introducers, Vascular plugs, Vessel closure/compression devices; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 3,784 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2031
U.S. locations: 7
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 4 more

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation (DBS); Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2038
U.S. locations: 29
States / cities: Aliso Viejo, California • Los Angeles, California • Aurora, Colorado + 25 more

Conditions: Pain
Interventions: neurostimulation system; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 4,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2035
U.S. locations: 67
States / cities: Phoenix, Arizona • Tucson, Arizona • Campbell, California + 60 more

Conditions: ATRT Recurrent, Ependymoma Recurrent, Medulloblastoma Recurrent, Rare CNS Tumor Recurrent
Interventions: Bevacizumab, Celecoxib, Cyclophosphamide, Cytarabine, Etoposide, Fenofibric acid, Irinotecan, Temozolomide (TMZ), Thalidomide; Drug
Lead sponsor: Medical University of Vienna; Other
Eligibility: Up to 19 Years
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2030
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Grand Rapids, Michigan + 1 more

Conditions: Friedreich Ataxia, Friedreich's Ataxia
Interventions: Nomlabofusp, Placebo; Drug
Lead sponsor: Larimar Therapeutics, Inc.; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Tampa, Florida • Chicago, Illinois • Eatontown, New Jersey + 1 more

Conditions: Corneal Edema, Corneal Endothelial Cell Loss, Corneal Endothelial Decompensation, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Endothelial Corneal Dystrophy, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions: 150K cells, 500K cells, Placebo; Biological · Procedure
Lead sponsor: Emmecell; Industry
Eligibility: 21 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Torrance, California • Largo, Florida • Atlanta, Georgia + 7 more

Conditions: Stroke
Interventions: Tele-CE, Tele-Control; Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: HIV, HIV Prevention, STIs, STIs Prevention
Interventions: Standard of care and PrEP Choice at Enrollment, Standard of care followed by PrEP Choice at Month 9; Other
Lead sponsor: Westat; Other
Eligibility: 13 Years to 24 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 6
States / cities: San Francisco, California • Washington D.C., District of Columbia • Tampa, Florida + 3 more

Conditions: Hernia
Interventions: ECLIPSIUM® System, Resorbable tacks (AbsorbaTack/SorbaFix); Device
Lead sponsor: Tissium; Industry
Eligibility: 22 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 12
States / cities: Loma Linda, California • Gainesville, Florida • Chicago, Illinois + 9 more

Conditions: Chronic Kidney Disease, Diabetes
Interventions: Attention control, CKD Awareness, Referrals, Education, and Support (CARES); Behavioral
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple System Atrophy
Interventions: TEV-56286; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D LLC; Industry
Eligibility: 30 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 10
States / cities: La Jolla, California • Boca Raton, Florida • Tampa, Florida + 6 more

Conditions: Colorectal Cancer
Interventions: Standard of Care, Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Huntsville, Alabama • Fullerton, California • Los Angeles, California + 18 more

Conditions: High-Risk Percutaneous Coronary Intervention (High-risk PCI)
Interventions: Elevate, Impella; Device
Lead sponsor: Magenta Medical Ltd.; Industry
Eligibility: 18 Years to 88 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 33
States / cities: Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 23 more

Conditions: Recurrent Pericarditis
Interventions: VTX2735; Drug
Lead sponsor: Zomagen Biosciences Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 15
States / cities: La Jolla, California • Orange, California • Saint Augustine, Florida + 10 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Cemiplimab, Computed Tomography, Dexamethasone, Docetaxel, Magnetic Resonance Imaging, Ramucirumab; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 378 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 413
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 335 more

Conditions: Relapsed/Refractory KMT2A-r Acute Leukemia, Relapsed/Refractory NPM1-m Acute Leukemia, Relapsed/Refractory NUP98-r Acute Leukemia
Interventions: Cytarabine, Fludarabine, Ziftomenib; Drug
Lead sponsor: PedAL BCU, LLC; Other
Eligibility: 0 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 8 more

Conditions: Endometrial Cancer, Germ Cell Tumor, Ovarian Cancer, Ovarian Germ Cell Tumor, Testicular Germ Cell Tumor
Interventions: XmAb541; Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 15 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 17
States / cities: Duarte, California • Palo Alto, California • San Francisco, California + 14 more

Conditions: Lung Non-Small Cell Carcinoma
Interventions: Amivantamab, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging; Biological · Procedure
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 271
States / cities: Jonesboro, Arkansas • Little Rock, Arkansas • Auburn, California + 229 more

Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab, Tepotinib; Procedure · Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Minutes and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 278
States / cities: Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 232 more

Conditions: Awake Fiberoptic Intubation, Difficult Airway
Interventions: Dexmedetomidine; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2034
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lennox Gastaut Syndrome
Interventions: Clemizole HCl, Placebo; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 2 Years to 55 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 22
States / cities: Little Rock, Arkansas • Orange, California • Miami, Florida + 16 more

Conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia
Interventions: cobicistat, revumenib; Drug
Lead sponsor: Syndax Pharmaceuticals; Industry
Eligibility: 30 Days and older
Enrollment: 447 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 22
States / cities: Duarte, California • Los Angeles, California • Palo Alto, California + 17 more

Search by objective public record fields.

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Isatuximab in Combination With Novel Agents in RRMM - Master Protocol

Abbott Vascular Medical Device Registry

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

RELIEF - A Global Prospective Observational Post-Market Study to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain

Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors

A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Tele-CE in Severe Stroke

Combatting HIV Or Other STIs Early (CHOOSE)

AtraUmatic Laparoscopic HerNia Repair Clinical Investigation to Evaluate the Safety and Performance of The ECLIPSIUM System for Mesh Fixation IDE

CKD Awareness, Referrals, Education, and Support Intervention for Early-Stage CKD

An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease

ELEVATE High-Risk PCI Pivotal Study

An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Comparison of Two Sedation Regimens for Awake Fiberoptic Intubation

An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation